BIO Asia–Taiwan 2022 showcases innovation, market, supply and investment
BIO Asia–Taiwan 2022 collated global biotechnology and
pharmaceutical executives and investors exploring business opportunities with
Taiwan’s emerging biotech sector. The event hosted around 1,500 participants
from over 30 nations, offerings from 15 countries in more than 1,500 booths,
and showcased around 550 bio-industry manufacturers.
BIO Asia–Taiwan 2022 International Conference and Exhibition
was held in Taiwan’s capital city Taipei in a hybrid version (Onsite + Virtual)
from July 27 to 29, 2022. The exhibition showcased the latest achievements in
the industry, academia, and research institutes, surpassing 100,000 visitors
over 4 days.
The Taiwan Bio Industry Organization (Taiwan BIO) and the
global Biotechnology Innovation Organization (BIO) Jointly organised BIO Asia–Taiwan
2022 under the keynote theme 'Connecting the Asian Value Chain' at the TaiNEX 2
Exhibition Center located in Nangang District of Taipei.
The active involvement of government research institutes
like Academia Sinica, the Ministry of Health and Welfare, the National Health
Research Institutes, the Institute of Nuclear Energy Research, the Development
Center for Biotechnology (DCB), and the Ministry of Economic Affairs’
Biotechnology and the Biotechnology and Pharmaceutical Industries Promotion
Office (BPIPO) were the major highlights at the event.
Furthermore, a key BioMed Commercialisation Center, comprising 13 research teams from the “Research Center for Epidemic Prevention Science'' demonstrated some of Taiwan's most promising license-ready technologies. In addition, the National Science and Technology Council led the Hsinchu Science Park, the Central Taiwan Science Park, the Southern Taiwan Science Park, the Taiwan Instrument Research Institute, and 36 other industry players showcased their innovations in drug discovery, medical materials, telemedicine, medical cosmetics, and carbon net zero firms. Similarly, an independent session on Novel Platforms for Biopharma Discovery was headed by Taiwan’s Biomedical Translation Research Center (BioTReC) of the Academia Sinica.
